Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment guidelines in heart failure

M A Konstam1, W J Remme

  • 1Heart Failure and Cardiac Transplant Center, Tufts University and New England Medical Center, Boston, MA 02111-1533, USA.

Progress in Cardiovascular Diseases
|August 26, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulation of the renin-angiotensin-aldosterone system - pivotal in heart failure treatment.

Zeitschrift fur Kardiologie·2016
Same author

Increased visit-to-visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: Insights from the HEAAL study.

International journal of cardiology·2015
Same author

Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study.

International journal of cardiology·2014
Same author

Clinical trials update from the European Society of Cardiology congress in Munich, 2008: TIME-CHF, CARESS-in-AMI, TRITON-TIMI 38, EUROPA, AF-CHF, and ADVANCE.

Cardiovascular drugs and therapy·2008
Same author

Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.

Cardiovascular drugs and therapy·2007
Same author

ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial.

Cardiovascular drugs and therapy·2007
Same journal

Beyond therapeutic maximalism: Prioritization and personalization in preventive therapies.

Progress in cardiovascular diseases·2026
Same journal

Multimodality imaging of vulnerable plaque: Are we there yet? A multifaceted perspective.

Progress in cardiovascular diseases·2026
Same journal

Beyond LDL-C: Triangulating residual risk via lipoprotein(a), remnant cholesterol, and vascular inflammation.

Progress in cardiovascular diseases·2026
Same journal

COVID-19 and coronary atherosclerosis: Unmasking and accelerating?

Progress in cardiovascular diseases·2026
Same journal

Mavacamten and left ventricular dysfunction in hypertrophic cardiomyopathy with left bundle branch block.

Progress in cardiovascular diseases·2026
Same journal

Lessons from ATTR-CM clinical trials: Progress, persistent disparities, and emerging treatment dilemmas.

Progress in cardiovascular diseases·2026
See all related articles

Heart failure risk rises with age, impacting many older adults. Recent European guidelines offer updated management strategies, including new data on beta-blockers like carvedilol for improved patient outcomes.

Area of Science:

  • Cardiology
  • Geriatrics
  • Public Health

Background:

  • Heart failure (HF) is a growing concern, particularly in aging populations, with a high mortality rate.
  • Effective management of HF is crucial due to its complexity and poor prognosis.

Purpose of the Study:

  • To summarize current guidelines for diagnosing and managing heart failure.
  • To highlight recent therapeutic advancements and their impact on patient care.

Main Methods:

  • Review of updated European and US cardiology guidelines for heart failure management.
  • Inclusion of recent data on pharmacological interventions, specifically beta-blockers.

Main Results:

  • European guidelines incorporate the latest evidence on beta-blockers, such as carvedilol, demonstrating benefits in mild-to-moderate heart failure.

Related Experiment Videos

  • Updated guidelines aim to improve the appropriateness and cost-effectiveness of HF patient management.

    • Conclusions:

    • The management of heart failure is evolving rapidly, necessitating regular guideline updates.
    • New therapeutic strategies, including specific beta-blockers, offer improved morbidity and mortality benefits for heart failure patients.